Temasek cuts stake in Celltrion and affiliate for $1b

Singapore’s sovereign wealth fund continues to fine-tune portfolio as it sells a small chunk of its shareholding in South Korea’s Celltrion and Celltrion Healthcare in overnight block deal.

Danny Leung

March 07, 2018

Temasek cashed out part of its investment in South Korean biopharmaceutical firm Celltrion and its affiliate Celltrion Healthcare for a combined W1.07 trillion ($994 million) on Tuesday, as the Singaporean sovereign wealth fund continues to reshape its portfolio to address long-term opportunities.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.